{"id":6290,"date":"2025-08-05T07:00:00","date_gmt":"2025-08-05T07:00:00","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=rkd-news&#038;p=6290"},"modified":"2025-10-14T13:04:45","modified_gmt":"2025-10-14T13:04:45","slug":"informed-healthcare-for-patients-with-igan","status":"publish","type":"rkd-news","link":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/","title":{"rendered":"Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1921\" height=\"1081\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-290x163.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-120px * var(--scale));\" class=\"section-container wp-elements-9f902b25a33304e92a2b36314319fc7e wp-block-grizzly-section-container has-text-color has-white-color\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on August 5, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Finformed-healthcare-for-patients-with-igan%2F&#038;text=Engaging+Patients+for+Better+Outcomes%3A+Informed+Care+for+IgA+Nephropathy\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Finformed-healthcare-for-patients-with-igan%2F&#038;title=Engaging+Patients+for+Better+Outcomes%3A+Informed+Care+for+IgA+Nephropathy\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Finformed-healthcare-for-patients-with-igan%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Engaging%20Patients%20for%20Better%20Outcomes%3A%20Informed%20Care%20for%20IgA%20Nephropathy&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Finformed-healthcare-for-patients-with-igan%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/6290#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">In this issue we: <\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li><a href=\"#h-iga-nephropathy-is-a-rare-progressive-kidney-disease-with-a-significant-lifetime-risk-of-kidney-failure-2-3\">Share helpful patient education resources and practical considerations for IgA nephropathy management<\/a><\/li>\n<li><a href=\"#h-estimated-glomerular-filtration-rate-egfr-and-proteinuria-are-measures-of-kidney-function-and-failure-3\">Review how IgA nephropathy develops and progresses over time, and the importance of early diagnosis and intervention<\/a><\/li>\n<li><a href=\"#h-ensuring-an-early-diagnosis-identifying-at-risk-patients-and-implementing-new-treatment-goals-are-essential-to-improve-long-term-outcomes-for-patients-8\">Explore the potential benefits of a dual-mechanism, kidney-targeted treatment strategy<\/a><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"event-video\" id=\"video\">\n\t\t\t<p class=\"has-heading-3-font-size\">Welcome by Ian Chiu<\/p>\n\t\t\n\t<a href=\"#\" class=\"event-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-ANNA-Newsletter-KOL-Thumbnail-V00-01-20250722_Thumbnail.webp');\">\n\t\t<span class=\"icon2-play\" aria-hidden=\"true\"><\/span>\n\t<\/a>\n\t\n\t<div class=\"event-video--vimeo\"><\/div>\n\t\n\t<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".event-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".event-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1103545330\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.allowFullscreen = true;\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\t\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1103545330');\n\t\t});\n\t});\n<\/script>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-iga-nephropathy-is-a-rare-progressive-kidney-disease-with-a-significant-lifetime-risk-of-kidney-failure-2-3\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">IgA nephropathy is a rare, progressive kidney disease with a significant lifetime risk of kidney failure<sup>2,3<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>In IgA nephropathy, IgA immune complexes are deposited into the mesangium, leading to upregulation of endothelin-1 (ET-1) and angiotensin II (Ang II), two key disease mediators.<sup>4<\/sup> Together, they drive ongoing kidney damage, resulting in proteinuria and glomerulosclerosis.<sup>4<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2470\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-scaled.webp 2470w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-289x300.webp 289w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-988x1024.webp 988w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-768x796.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-1482x1536.webp 1482w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-1976x2048.webp 1976w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250723_Figure-4-290x301.webp 290w\" sizes=\"auto, (max-width: 2470px) 100vw, 2470px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. Framing the underlying mechanism of IgA nephropathy for patient discussions<sup>5<\/sup><br \/>\r\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-estimated-glomerular-filtration-rate-egfr-and-proteinuria-are-measures-of-kidney-function-and-failure-3\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Estimated glomerular filtration rate (eGFR) and proteinuria are measures of kidney function and failure<sup>3<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Proteinuria is the only validated early biomarker to help guide clinical decision-making, and persistent proteinuria is the single strongest and modifiable prognostic indicator for IgA nephropathy disease progression.<sup>6-8<\/sup><\/p>\n<p>Although proteinuria levels below 1 g\/day were traditionally considered &#8220;low risk&#8221;, data from the UK RaDaR registry show many of those patients with IgA nephropathy still progress to kidney failure.<sup>3<\/sup> These findings reinforce the urgency of pursuing greater proteinuria reductions (<0.3 g\/day) and early, kidney-targeted treatment.<sup>3,9<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Patient education may include information on the clinical significance of both eGFR and proteinuria<sup>3,8<\/sup>:<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul style=\"padding-left:calc(50px * var(--scale))\" class=\"wp-block-list\">\n<li>Proteinuria is a marker of active kidney damage and an indicator for intervention<\/li>\n\n\n\n<li>eGFR represents a longer-term measure, indicating overall kidney function and trajectory<\/li>\n<\/ul>\n<\/div>\n\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2501\" height=\"1689\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5.webp 2501w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-300x203.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-1024x692.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-768x519.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-1536x1037.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-2048x1383.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-02-20250718_Figure-5-290x196.webp 290w\" sizes=\"auto, (max-width: 2501px) 100vw, 2501px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. Patient-friendly explanation of proteinuria and eGFR levels<sup>8,10<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-ensuring-an-early-diagnosis-identifying-at-risk-patients-and-implementing-new-treatment-goals-are-essential-to-improve-long-term-outcomes-for-patients-8\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Ensuring an early diagnosis, identifying at-risk patients, and implementing new treatment goals are essential to improve long\u2011term outcomes for patients<sup>8<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Historically, standard of care (SOC) focused on supportive care, lifestyle management, rigorous blood pressure control with renin-angiotensin system inhibitors (RASi), and immunosuppression.<sup>11<\/sup> However, SOC was often insufficient\u2014this unmet need for many patients fueled a &#8220;renal renaissance&#8221; in IgA nephropathy treatment, leading to the approval of new therapies.<sup>12,13<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2501\" height=\"1391\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1.webp 2501w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-300x167.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-1024x570.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-768x427.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-1536x854.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-2048x1139.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1455-Travere-RKD-News-ANNA-2025-Visuals-for-email-V01-01-20250521_Figure-1-290x161.webp 290w\" sizes=\"auto, (max-width: 2501px) 100vw, 2501px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. Emerging trends in kidney disease management<sup>8<\/sup><br \/>\r\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-a-dual-endothelin-angiotensin-receptor-antagonist-deara-represents-a-novel-non-immunosuppressive-approach-to-treating-iga-nephropathy-4\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">A dual endothelin angiotensin receptor antagonist (DEARA) represents a novel, non\u2011immunosuppressive approach to treating IgA nephropathy<sup>4<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>A DEARA inhibits two key pathways implicated in kidney damage in IgA nephropathy, ET-1 and Ang II.<sup>4,5,14<\/sup> By targeting both pathways simultaneously, a DEARA helps reduce proteinuria and preserve kidney function over time without the need for immunosuppression.<sup>4,14<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-management-of-iga-nephropathy-has-seen-significant-advancements-over-the-last-several-years-8-11-12\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Management of IgA nephropathy has seen significant advancements over the last several years<sup>8,11,12<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>From a growing understanding of the disease to newly approved therapies, there is a drive to improve patient outcomes.<sup>3,12<\/sup> IgA nephropathy is not the benign disease it was once thought to be, making patient awareness and education vital.<sup>3<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-ae2998e762e75c059bf0a550d3f8cbfa\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong>Footnotes<\/strong><\/h5>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Gagliardi AR et al. BMC <em>Med Inform Decis Mak<\/em>. 2020;20(1):231.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Mcgrogan A et al. <em>Nephrol Dial Transplant.<\/em> 2010;26(2):414-430.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Pitcher D et al. <em>Clin J Am Soc Nephrol.<\/em> 2023;18(6):727-738.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci (Lond).<\/em> 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Lai KN et al. <em>Nat Rev Dis Primers.<\/em> 2016;2:16001.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Inker LA et al. <em>Am J Kidney Dis.<\/em> 2016;68(3):392-401.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Reich HN et al. <em>J Am Soc Nephrol. <\/em>2007;18(12):3177-3183.<\/li>\n\n\n\n<li class=\"has-small-font-size\">KDIGO Clinical Practice Guidelines for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Accessed 22 October 2024. <a href=\"https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf\"><span class=\"text-decoration-underline\">https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf<\/span><\/a><\/li>\n\n\n\n<li class=\"has-small-font-size\">Floege J et al. <em>Kidney International.<\/em> 2025;107(4):640-651.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Inker LA et al. <em>Am J Kidney Dis.<\/em> 2021;78(5):736-749.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. <em>Kidney Int.<\/em> 2021;100(4S):S1-S276.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Cheung CK and Barratt J. <em>Semin Nephrol<\/em>. 2024;44(5):151573.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>Expert Rev Clin Immunol.<\/em> 2024;20(6):571-576.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right has-small-font-size\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-DS-25-0049 | July 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":6279,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[],"therapeutic_area":[97],"disease_area":[174],"study_registry":[],"study_type":[],"resource_type":[208],"class_list":["post-6290","rkd-news","type-rkd-news","status-publish","has-post-thumbnail","hentry","therapeutic_area-neph","disease_area-igan","resource_type-newsletter"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rare Kidney Disease News | Engaging Patients for Better Outcomes in IgAN - Travere Medical Affairs<\/title>\n<meta name=\"description\" content=\"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy\" \/>\n<meta property=\"og:description\" content=\"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T13:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1921\" \/>\n\t<meta property=\"og:image:height\" content=\"1081\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/\",\"name\":\"Rare Kidney Disease News | Engaging Patients for Better Outcomes in IgAN - Travere Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\",\"datePublished\":\"2025-08-05T07:00:00+00:00\",\"dateModified\":\"2025-10-14T13:04:45+00:00\",\"description\":\"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\",\"width\":1921,\"height\":1081},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/informed-healthcare-for-patients-with-igan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advanced Practice Practitioners: IgAN Patient Education\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Kidney Disease News | Engaging Patients for Better Outcomes in IgAN - Travere Medical Affairs","description":"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy","og_description":"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care","og_url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-14T13:04:45+00:00","og_image":[{"width":1921,"height":1081,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/","url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/","name":"Rare Kidney Disease News | Engaging Patients for Better Outcomes in IgAN - Travere Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp","datePublished":"2025-08-05T07:00:00+00:00","dateModified":"2025-10-14T13:04:45+00:00","description":"Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp","width":1921,"height":1081},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"Advanced Practice Practitioners: IgAN Patient Education"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 19:46:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"therapeutic_area","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/6290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/rkd-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/6279"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=6290"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=6290"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=6290"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=6290"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=6290"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=6290"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=6290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}